[血清爱泼斯坦-巴尔病毒核抗原1（EBNA1）/潜伏膜蛋白1（LMP1）检测在鼻型结外NK/T细胞淋巴瘤患者中的临床意义]

[The clinical significance of serum Epstein-Barr virus-determined nuclear antigen 1 (EBNA1)/latent membrane protein 1 (LMP1) assay in patients with nasal type extranodal NK/T-cell lymphoma].

作者信息

Yao Na, Cui Xueying, Wang Jingwen

机构信息

Department of Hematology, Beijing Tongren Hospital, Capital Medical University,Beijing 100730, China.

Department of Hematology, Beijing Tongren Hospital, Capital Medical University,Beijing 100730, China. Email:

出版信息

Zhonghua Nei Ke Za Zhi. 2015 Feb;54(2):106-10.

PMID:25907839

Abstract

OBJECTIVE

To explore the clinical significance of the serum Epstein-Barr virus-determined nuclear antigen 1 (EBNA1)/latent membrane protein 1 (LMP1) in patients with extranodal NK/T-cell lymphoma, nasal type (ENKL).

METHODS

The serum EBNA1 and LMP1 were detected by real-time PCR in 36 ENKL patients hospitalized in Beijing Tongren Hospital from August 2010 to August 2013. Twenty healthy volunteers were recruited as controls.

RESULTS

The median serum EBNA1 was 1.9×10(4) (ranged from 0 to 11.0×10(4)) copies/µl in ENKL patients and 8.0 (ranged from 0 to 43.8) copies/µl in healthy volunteers. The median serum LMP1 was 3.9×10(3) (ranged from 118.3 to 24.0×10(3)) copies/µl in ENKL patients and 3.3 (ranged from 0 to 33.3) copies/µl in healthy volunteers. Both EBNA1 and LMP1 were higher in ENKL patients than healthy volunteers (all P < 0.01). The median EBNA1 and LMP1 in ENKL patients posttreatment were 1.0×10(3) (ranged from 0 to 2.0 × 10(3)) copies/µl and 300.8 (ranged from 0 to 825.7) copies/µl respectively, which were both significantly decreased than pretreatment (all P < 0.05). The EBNA1 and LMP1 were decreased in effective treatment group versus ineffective treatment group (P < 0.05). The serum EBNA1 and LMP1 were positively correlated with lactic dehydrogenase (LDH) level (r = 0.364,0.546; P = 0.040,0.012).

CONCLUSIONS

(1) The measurement of EBNA1/LMP1 may be useful in evaluating the therapeutic effect. (2) The serum EBNA1/LMP1 may reflect the tumor load in ENKL patients.

摘要

目的

探讨血清爱泼斯坦-巴尔病毒核抗原1（EBNA1）/潜伏膜蛋白1（LMP1）在鼻型结外NK/T细胞淋巴瘤（ENKL）患者中的临床意义。

方法

采用实时荧光定量PCR法检测2010年8月至2013年8月在北京同仁医院住院的36例ENKL患者血清中的EBNA1和LMP1。招募20名健康志愿者作为对照。

结果

ENKL患者血清EBNA1中位数为1.9×10⁴（范围0～11.0×10⁴）拷贝/微升，健康志愿者为8.0（范围0～43.8）拷贝/微升。ENKL患者血清LMP1中位数为3.9×10³（范围118.3～24.0×10³）拷贝/微升，健康志愿者为3.3（范围0～33.3）拷贝/微升。ENKL患者的EBNA1和LMP1均高于健康志愿者（均P＜0.01）。ENKL患者治疗后EBNA1和LMP1中位数分别为1.0×10³（范围0～2.0×10³）拷贝/微升和300.8（范围0～825.7）拷贝/微升，均较治疗前显著降低（均P＜0.05）。有效治疗组的EBNA1和LMP1较无效治疗组降低（P＜0.05）。血清EBNA1和LMP1与乳酸脱氢酶（LDH）水平呈正相关（r = 0.364，0.546；P = 0.040，0.012）。